First Over-the-Counter CBD Pain Medication Gets FDA Nod

February 5, 2020 09:00:02

Cannabinoids have presented a new avenue in medicine, at least according to current research. The cannabis plant produces over 100 of these chemicals, and although most of them are still shrouded in mystery, we know quite a bit about two of them, THC (delta-9 tetrahydrocannabinol), and cannabidiol (CBD).

THC is responsible for the psychoactive high marijuana is famous for, and it has mild medicinal properties. CBD, on the other hand, isn’t psychoactive. It is, however, seen as a potent natural medicine.

Although scientific research is scant, people who’ve used cannabidiol say the chemical works against a variety of ailments. The list ranges from anxiety and pain to high blood pressure and insomnia.

Here’s a little good news for CBD proponents; A CBD-infused topical drug has just received over the counter certification by the U.S. Food and Drug Administration (FDA). Called Elixicure, it is the first ever over-the-counter topical drug with cannabidiol to receive certification.

It is an all-natural, non-addictive pain relief cream developed to help reduce inflammation, swelling, aches and pains. Elixicure Chief of Business Development Yaniv Kotler says the firm is ecstatic about the certification of its new CBD-infused topical.

“This is a major milestone in our commitment to quality and offering customers healthier options for pain relief using effective natural products, as an alternative to opioids and other dangerous pharmaceuticals.”

The topical is also certified by the Banned Substance Control Group (BSCG), which offers a complete suite of certification, testing and GMP compliance services to the dietary supplement and natural product communities, and is safe for use by athletes at all competitive levels.

“Customer trust is important to us. Unlike so many companies that market CBD and CBD products, our business model has always been driven by quality and compliance, which is verified by third party certifiers. This certification requires us to vet our processes, our equipment and systems, our vendors and suppliers, and conduct batch-to-batch testing to ensure quality.”

Elixicure’s BSCG certification proves that the product doesn’t contain any heavy metals, microbials and THC, and certifies the amount of CBD present and other active ingredients. According to Yaniv, the FDA’s certification provides customers with an alternative to opioids for pain relief.

Elixicure joins an exclusive club of CBD-based drugs that have gained the FDA’s nod of approval, with the only other member being Epidiolex. It was developed by British pharmaceutical company GW Pharma, to manage seizures caused by two rare and hard to treat pediatric epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome.

It would be enlightening to hear what CBD companies like Inc. (OTCQB: CIIX) have to say about the ramifications of having CBD-based drugs getting federal approval and yet the industry is fighting to see that CBD is permitted for use in food, drinks and supplements.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.